Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drug-Receptor Interactions01:29

Drug-Receptor Interactions

5.1K
Drug-receptor interaction describes the binding of receptors by drugs, but not all drug-receptor interactions result in activation and tissue response. For instance, the binding of agonists activates the receptor to generate a cellular reaction, while antagonists bind to receptors without causing their activation.
Several parameters, such as the drug's affinity for its receptor and its efficacy, which is its ability to activate the receptor, determine the drug's effect on the tissue....
5.1K
Drug-Receptor Interaction: Antagonist01:28

Drug-Receptor Interaction: Antagonist

2.8K
An antagonist is a drug that binds strongly to a receptor without activating it. An antagonist prevents other molecules, such as neurotransmitters or hormones, from binding to the receptor and triggering a cellular response. Such interaction effectively hinders the normal physiological processes mediated by the receptor, resulting in various pharmacological effects depending on the specific receptor targeted.
Antagonists can be classified as competitive or noncompetitive based on their...
2.8K
Combined Effects of Drugs: Antagonism01:30

Combined Effects of Drugs: Antagonism

8.4K
The combined effects of drugs can result in various interactions, of which an important type is antagonism. Antagonism is a mechanism where one drug inhibits or counteracts the effects of another drug. Antagonism can occur through various means, including receptor binding, allosteric modulation, functional interaction, chemical reactions, and pharmacokinetic processes.
The most common type is receptor antagonism, where one drug acts as an antagonist to block the effects of another drug by...
8.4K
Drug-Receptor Interaction: Agonist01:25

Drug-Receptor Interaction: Agonist

2.4K
Agonists are drugs that interact with specific receptors in the body to produce a biological response. When an agonist binds to a receptor, it activates or enhances the receptor's function, leading to physiological effects. The interaction between agonist drugs and receptors is crucial for their therapeutic action in various medical treatments.
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous...
2.4K
Combined Effects of Drugs: Synergism01:27

Combined Effects of Drugs: Synergism

3.8K
Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...
3.8K
Drug Dosage Regimen: Overview01:15

Drug Dosage Regimen: Overview

3.5K
A drug dosage regimen describes the specific instructions and schedule for administering a drug to a patient. It considers factors such as drug dosage, frequency, route of administration, and duration of treatment. Designing an appropriate dosage regimen for a patient aims to achieve a target drug concentration at the site of action.
Typically, the starting dose and dosing interval are guided by the manufacturer's recommendations based on clinical trials conducted during and after drug...
3.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Discovery of a New Scaffold RSK2 Inhibitor With Virtual and Phenotypical Screening.

ChemMedChem·2026
Same author

High-throughput signal detection of hepatotoxic drug-drug interactions in hospitalized elderly patients: an NLP-driven pharmacovigilance study.

Annals of medicine·2026
Same author

Ocular Adverse Events Associated With Antidepressants: A Large-Scale Data Analysis From the FAERS Database.

CNS neuroscience & therapeutics·2026
Same author

Safety, tolerability, and pharmacokinetics of HL-300, a novel topical pan-JAK inhibitor, in healthy Chinese adults: a first-in-human, randomized, double-blind, placebo-controlled phase I trial.

Expert opinion on investigational drugs·2026
Same author

Metabolic syndrome-osteoarthritis axis: Beyond mechanical loading toward a cardiometabolic OA phenotype.

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie·2026
Same author

A randomized controlled phase Ia clinical trial to evaluate the safety, tolerability and pharmacokinetic characteristics of tofacitinib tartrate cream (HZ-J001) in healthy Chinese subjects.

Frontiers in pharmacology·2026

Related Experiment Video

Updated: Jun 15, 2025

A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions
07:40

A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions

Published on: May 27, 2021

4.1K

DDInter 2.0: an enhanced drug interaction resource with expanded data coverage, new interaction types, and improved

Yao Tian1, Jiacai Yi2, Ningning Wang3

  • 1Xiangya School of Pharmaceutical Sciences, Central South University, Changsha, Hunan 410013, P.R. China.

Nucleic Acids Research
|August 24, 2024
PubMed
Summary
This summary is machine-generated.

DDInter 2.0 enhances drug interaction data, including drug-food, drug-disease, and therapeutic duplications. This comprehensive resource aids healthcare professionals in optimizing drug therapy and improving patient safety.

More Related Videos

Diagonal Method to Measure Synergy Among Any Number of Drugs
12:08

Diagonal Method to Measure Synergy Among Any Number of Drugs

Published on: June 21, 2018

18.5K
High-throughput Identification of Synergistic Drug Combinations by the Overlap2 Method
07:51

High-throughput Identification of Synergistic Drug Combinations by the Overlap2 Method

Published on: May 21, 2018

11.7K

Related Experiment Videos

Last Updated: Jun 15, 2025

A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions
07:40

A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions

Published on: May 27, 2021

4.1K
Diagonal Method to Measure Synergy Among Any Number of Drugs
12:08

Diagonal Method to Measure Synergy Among Any Number of Drugs

Published on: June 21, 2018

18.5K
High-throughput Identification of Synergistic Drug Combinations by the Overlap2 Method
07:51

High-throughput Identification of Synergistic Drug Combinations by the Overlap2 Method

Published on: May 21, 2018

11.7K

Area of Science:

  • Pharmacology
  • Clinical Informatics

Background:

  • Drug interactions are a major clinical challenge, exacerbated by increasing polypharmacy.
  • Existing resources often lack comprehensive coverage of diverse interaction types, impacting patient safety and treatment efficacy.

Purpose of the Study:

  • To introduce DDInter 2.0, an expanded and enhanced drug interaction database.
  • To provide healthcare professionals with a more complete and user-friendly resource for managing drug interactions.

Main Methods:

  • Expanded the drug interaction database to include drug-food interactions (DFIs), drug-disease interactions (DDSIs), and therapeutic duplications.
  • Updated the database to cover 2310 drugs with extensive records for drug-drug interactions (DDIs), DFIs, DDSIs, and therapeutic duplications.
  • Enhanced the user interface with advanced filtering for improved data access and analysis.

Main Results:

  • The DDInter 2.0 database contains 302,516 DDI records with 8,398 mechanism descriptions and management recommendations.
  • Includes 857 DFIs, 8,359 DDSIs, and 6,033 therapeutic duplication records, all with detailed guidance.
  • Features an improved interface for efficient data retrieval and analysis.

Conclusions:

  • DDInter 2.0 offers a significantly enhanced and comprehensive resource for drug interaction information.
  • The updated database and improved interface aim to support clinical decision-making and enhance patient outcomes.
  • DDInter 2.0 is freely accessible online to facilitate widespread adoption and use.